| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 17, 2021 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,751 | -- | 40,751 |
| Aug 17, 2021 |
Director
Trans History: 8
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,751 | -- | 40,751 |
| Aug 23, 2018 |
Ten Percent Owner
Trans History: 18
|
Ten Percent Owner | Form 4 | Conversion of derivative security | 40,268 | -- | -- |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Sep 18, 2023 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Jun 06, 2019 |
Director
Trans History: 8
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 30,274 | -- | 30,274 |
| Aug 23, 2018 |
Ten Percent Owner
Trans History: 18
|
Ten Percent Owner | Form 4 | Conversion of derivative security | 27,328 | -- | -- |
| May 26, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $0.56 | 33,000 |
| May 26, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | 200,000 |
| Oct 01, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 23,230 | -- | 23,230 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.